These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

909 related articles for article (PubMed ID: 32631294)

  • 1. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
    Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
    BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen X; Meng F; Jiang R
    Front Oncol; 2021; 11():746976. PubMed ID: 34900692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of preoperative lymphocyte-related systemic inflammatory biomarkers in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: a systematic review and meta-analysis.
    Shao Y; Li W; Wang D; Wu B
    World J Surg Oncol; 2020 Oct; 18(1):273. PubMed ID: 33097052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
    Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
    Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.
    Tan S; Zheng Q; Zhang W; Zhou M; Xia C; Feng W
    Front Immunol; 2024; 15():1408700. PubMed ID: 39050856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis.
    Yang T; Hao L; Yang X; Luo C; Wang G; Lin Cai C; Qi S; Li Z
    BMJ Open; 2021 Sep; 11(9):e049123. PubMed ID: 34475167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Stroke: A Systematic Review and Meta-Analysis.
    Li W; Hou M; Ding Z; Liu X; Shao Y; Li X
    Front Neurol; 2021; 12():686983. PubMed ID: 34630275
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis.
    Hu K; Lou L; Ye J; Zhang S
    BMJ Open; 2015 Apr; 5(4):e006404. PubMed ID: 25854964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
    Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
    Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of neutrophil-to-lymphocyte ratio for nasopharyngeal carcinoma: A meta-analysis.
    Yin J; Qin Y; Luo YK; Feng M; Lang JY
    Medicine (Baltimore); 2017 Jul; 96(29):e7577. PubMed ID: 28723793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in patients with laryngeal cancer: a systematic review and meta-analysis.
    Yang F; Huang Q; Guan Z; Diao Q
    Eur Arch Otorhinolaryngol; 2021 Feb; 278(2):417-425. PubMed ID: 32886184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors.
    Na N; Yao J; Cheng C; Huang Z; Hong L; Li H; Qiu J
    Oncotarget; 2016 Jul; 7(28):44039-44046. PubMed ID: 27270655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma.
    Dalpiaz O; Luef T; Seles M; Stotz M; Stojakovic T; Pummer K; Zigeuner R; Hutterer GC; Pichler M
    Br J Cancer; 2017 Jan; 116(1):85-90. PubMed ID: 27907929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients.
    Pichler M; Hutterer GC; Stoeckigt C; Chromecki TF; Stojakovic T; Golbeck S; Eberhard K; Gerger A; Mannweiler S; Pummer K; Zigeuner R
    Br J Cancer; 2013 Mar; 108(4):901-7. PubMed ID: 23385728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Shen J; Chen Z; Zhuang Q; Fan M; Ding T; Lu H; He X
    PLoS One; 2016; 11(11):e0166482. PubMed ID: 27861542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies.
    Mei Z; Shi L; Wang B; Yang J; Xiao Z; Du P; Wang Q; Yang W
    Cancer Treat Rev; 2017 Jul; 58():1-13. PubMed ID: 28602879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Young M; Tapia JC; Szabados B; Jovaisaite A; Jackson-Spence F; Nally E; Powles T
    Clin Genitourin Cancer; 2024 Jun; 22(3):102072. PubMed ID: 38615487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
    Gunduz S; Mutlu H; Uysal M; Coskun HS; Bozcuk H
    Asian Pac J Cancer Prev; 2014; 15(8):3801-4. PubMed ID: 24870797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.